Cost-per-responder analysis of tralokinumab versus dupilumab in patients with moderate-to-severe atopic dermatitis in the US and Canada

被引：0
|
作者：
Wu, Jashin J. [1 ]
Balu, Sanjeev [2 ]
Larsen, Nikolaj Birk [3 ]
Pulleyblank, Ryan [3 ]
Stromkjaer, Liv [3 ]
Quah, Aron [4 ]
Wiseman, Marni [5 ,6 ]
机构：
[1] Univ Miami, Miller Sch Med, Dept Dermatol, Miami, FL USA
[2] LEO Pharma, Madison, NJ USA
[3] NHTA ApS, Copenhagen, Denmark
[4] LEO Pharma, N York, ON, Canada
[5] Univ Manitoba, Dept Med, Sect Dermatol, Winnipeg, MB, Canada
[6] Wiseman Dermatol Res, Winnipeg, MB, Canada
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 190卷
关键词：
matching-adjusted indirect comparison; moderate-to-severe; tralokinumab;
D O I：
10.1093/bjd/ljad498.044
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
544
引用
收藏
页码：II42 / II43
页数：2
相关论文
共 50 条
  • [1] COST-PER-RESPONDER ANALYSIS OF TRALOKINUMAB AND DUPILUMAB IN THE TREATMENT OF MODERATETO-SEVERE ATOPIC DERMATITIS
    Torres, T.
    Ryttig, L.
    Larsen, N.
    Pulleyblank, R.
    Stromkjaer, L.
    Carrascosa, J. M.
    VALUE IN HEALTH, 2023, 26 (12) : S130 - S130
  • [2] Cost per responder of upadacitinib 30 mg and dupilumab 300 mg in patients with moderate-to-severe atopic dermatitis in italy
    Stingeni, Luca
    Ravasio, Roberto
    Palladino, Chiara
    Di Fino, Sara
    Levi, Anna
    Ronci, Gianluca
    Gisondi, Paolo
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2025, 12 : 70 - 79
  • [3] BUDGET IMPACT ANALYSIS OF TRALOKINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS IN THE UK
    Chalmers, K.
    Sawyer, L.
    Sohrt, A.
    Robinson, S.
    Ryttig, L.
    Rinciog, C.
    VALUE IN HEALTH, 2022, 25 (12) : S124 - S124
  • [4] Dupilumab in the treatment of moderate-to-severe atopic dermatitis
    Kraft, Magdalena
    Worm, Margitta
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (04) : 301 - 310
  • [5] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
    James E. Frampton
    Hannah A. Blair
    American Journal of Clinical Dermatology, 2018, 19 : 617 - 624
  • [6] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
    Frampton, James E.
    Blair, Hannah A.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (04) : 617 - 624
  • [7] Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice
    Schloesser, Anne R.
    Shareef, Madena
    Olydam, Jill
    Nijsten, Tamar E. C.
    Hijnen, Dirk Jan
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2023, 48 (05) : 510 - 517
  • [8] NUMBER NEEDED TO TREAT AND ASSOCIATED COSTS/ ADDITIONAL RESPONDER OF DUPILUMAB VERSUS TRALOKINUMAB IN ADULT PATIENTS WITH MODERATE- TO-SEVERE ATOPIC DERMATITIS
    Tavi, J.
    Noonan, K.
    Kuznik, A.
    Hudson, R.
    VALUE IN HEALTH, 2024, 27 (12)
  • [9] Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis
    Zimmermann, Marita
    Rind, David
    Chapman, Rick
    Kumar, Varun
    Kahn, Sonya
    Carlson, Josh
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (07) : 750 - 756
  • [10] Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis
    Edwards, Steven J.
    Karner, Charlotta
    Jhita, Tracey
    Barton, Samantha
    Marceniuk, Gemma
    Yiu, Zenas Z. N.
    Wittmann, Miriam
    HEALTH TECHNOLOGY ASSESSMENT, 2024, 28 (04)
12345